| | | June 9, 2022 Hey traders! It's Michael here with the BRAND NEW Stock Dork Premarket Report, your go-to guide for the day's biggest trading news and hottest premarket stocks! Today is Thursday, June 9th. Let's get ready to trade! |
US indices posted losses on Wednesday, as the S&P 500 fell 1.1% and the Nasdaq lost 0.7% on the trading session. The Dow slid to a 0.8% decline, and the small-cap Russell 2K index tumbled 1.5%. Today, S&P 500 futures are up 0.5% in early morning trading, so the benchmark index could open today's session with gains. Wejo Group Ltd [WEJO] - Last Close: $2.24 Wejo Group is up after a big announcement this morning. The cloud services company announced that it will expand and extend its collaboration with Microsoft Corp's Microsoft Maps. According to company statements, the collaboration will significantly advance Microsoft's mapping products in multiple global territories. Microsoft will also receive real-time Wejo data from all territories to further enhance and improve its mapping capabilities. "The accuracy and reliability of Wejo's data has allowed us to develop significant improvements to our mapping services for millions of Bing Maps users," Microsoft VP Nick Lee said.
WEJO is trading actively with a 27.2% gain on the news. Our Take: The sky is the limit with Microsoft on your side. Wejo could be a promising small-cap cloud stock, judging by Microsoft's confidence in the company's technology and capabilities. Bluejay Diagnostics [BJDX] - Last Close: $1.29 Bluejay Diagnostics has struck a promising new deal with regulators. This morning, the diagnostics company announced that the US Food & Drug Administration has improved its plan to pursue a De Novo submission for its Symphony IL-6 Test. In its written feedback to Bluejay's January 2022 submission of the FDA pre-submission briefing package, the FDA stated that Bluejay's Symphony IL-6 Test could be considered for the De Novo pathway. Bluejay CEO Neil Dey said on the subject, "We are excited for the opportunity to pursue the De Novo regulatory pathway. This confirms our belief that the Bluejay Symphony IL-6 Test has the potential to provide an innovative solution to the market". Dey also said, "Bluejay continues to advance the Symphony IL-6 Test towards the Company's anticipated marketing application with the FDA, expected by year-end 2022." BJDX is trading actively with a 40.3% gain. Our Take:A De Novo pathway puts Bluejay on the fast track to approval for its Symphony IL-6 test. However, the good news might be largely priced in after this announcement. Sonnet Therapeutics [SONN] - Last Close: $0.2400 Sonnet Therapeutics is rallying on new clinical data from key drug trials. The clinical-stage oncology-focused biotech company announced results from a preclinical combination study of SON-1010 with anti-PD1 checkpoint inhibition this morning. The study showed that a combination of SON-1010 and a commercially available anti-PD1 antibody inhibited tumor volume growth and increased survivability. Sonnet says this data will guide future combination study designs on SON-1010 and checkpoint inhibitors. SONN is trading actively with a 30.5% gain in the premarket. Our Take: Sonnet's push to explore combination treatments for SON-1010 could be paying off. It's still early, but if the company can refine its approach, there could be additional catalysts in this stock's future. SeaChange International [SEAC] - Last Close: $0.7475 SeaChange is up after a quarterly earnings release.
The video content and advertising stock reported its fiscal Q1 results after Wednesday's closing bell. SeaChange reported a narrowed operating loss of $(0.03) per share in its fiscal Q1, marking a sharp improvement from last year's $(0.07) per share loss. The company also said its core business grew revenues 33% YoY and reported Q1 sales of $6.7 million, up from the year-earlier quarter's $5.1 million figure. SeaChange also noted "dramatically" reduced costs and said it's looking forward to a "better than break-even outlook" this year.
SEAC is up 10.4% on active trading volume. Our Take: SeaChange's earnings report showed signs of progress at the company, including strong revenue growth, but I didn't see anything that makes me want to scream "buy!" |
| Gainers Rigel [RIGL] >> +6.7% Athersys [ATHX] >> +12.4% Athara Biotherapeutics [ATRA] >> +19.7% Decliners Bilibili Inc [BILI] >> (12.1%) Kinetik Holdings [AERC] >> (49.0%) MDJM Ltd [MDJH] >> (19.0%) Signet Jewelers [SIG] ... AM Bilibili [BILI] ... AM Fuelcell Energy [FCEL] ... AM Vail Resorts [MTN] ... PM DocuSign [DOCU] ... PM Stitch Fix [SFIX] ... PM |
| Initial Jobless Claims [Apr] ... 8:30a Real Household Net Worth [Q1] ... 12p |
| Thanks for reading! Don't forget, I'm always eager to hear from you. Reply to this email with your questions, comments, or general feedback, and I'll get back to you as soon as I can. Wishing you big returns on your investments this week, as always! - Michael "The Stock Dork" Taylor P.S. Want My Alerts Delivered To Your Cell Phone? Sign up for mobile alerts and get the latest updates delivered to your cell. Disclaimer © 2022 TheStockDork.com. All rights reserved. This message was sent by TheStockDork.com and may contain commercial elements such as advertising. Read full terms here. |
|
|
|
| | |
|
